Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05565417 · ClinicalTrials.gov registry record · Phase 1
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
A Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Immunitas Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
- 9
- Study locations
NCT05565417: Active Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Immunitas Therapeutics.
NCT05565417 is a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer that is active but no longer recruiting, run by Immunitas Therapeutics. The registered enrollment target is 67 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05565417, a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, is active but no longer recruiting, sponsored by Immunitas Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: * Find the recommended dose of IMT-009 that can be safely given to participants * Learn more about the side effects of IMT-009 * Learn more about pharmacokinetics of IMT-009 * Learn more about the effectiveness of IMT-009 * Learn more about different pharmacokinetic biomarkers and how they might change in the presence of IMT-009
Conditions Studied
Interventions
- DRUG IMT-009
- COMBINATION_PRODUCT Fruquintinib
Study Locations (9)
Florida
- Site 4100 - Orlando
- Site 4060 - Sarasota
Arizona
- Site 9618 - Tucson
Colorado
- Site 5000 - Denver
Oklahoma
- Site 4500 - Oklahoma City
Oregon
- Site 9280 - Portland
Tennessee
- Site 3000 - Nashville
Texas
- Site 9384 - Austin
Virginia
- Site 9112 - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2022-11-28 |
| Est. Completion | 2026-01 |
| Phase | Phase 1 |
What the registry record for NCT05565417 still lists
NCT05565417 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower).
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which IMT-009 is the first listed.
NCT05565417 lists 9 locations in 8 states (Florida, Arizona, Colorado).
Frequently Asked Questions
What is clinical trial NCT05565417 about?
NCT05565417 is a clinical study titled "Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas". This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: * Find the recommended dose of IMT-009 that can be safely ...
What is the current status of trial NCT05565417?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2022-11-28. Estimated completion is 2026-01.
What conditions does trial NCT05565417 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer.
What interventions are being tested in trial NCT05565417?
The interventions under investigation include: IMT-009 (DRUG), Fruquintinib (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05565417?
This trial is sponsored by Immunitas Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05565417 being conducted?
This trial has 9 study locations across Arizona, Colorado, Florida, Oklahoma, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05565417's enrollment target sits among peer trials
67 298th of 454 higher than 155 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI